Obesity-Related Asthma: Translating the Science into the Clinic

Obesity is associated with increased asthma risk and morbidity. In this module, we will review some of the underlying mechanisms of obese asthma, and the importance of recognizing that this complex phenotype is comprised of different sub-phenotypes and endotypes. We will then examine different approaches for the management of patients with obesity and asthma, including lifestyle changes, medical and surgical weight loss, and novel pharmacological approaches. Finally, we will discuss knowledge gaps and future directions in the field.

This course is an edited and enhanced recording of the ATS 2022 International Conference session with the same name.

Grant Support: This educational module is supported by an independent medical educational grant from Genentech, Inc.

Target Audience

Clinicians (physicians, nurses, fellows, residents), researchers, administrators, and policymakers: anyone involved in the delivery of care and the science of patients with asthma

Learning Objectives

After successfully completing this module, learners will be able to:

  • Identity the heterogeneity of obese asthma, including subphenotypes and endotypes related to atopy, systemic inflammation, and metabolic dysregulation; and describe their impact on asthma management
  • Describe and highlight the importance of lifestyle modifications, medical, and surgical weight loss in the management of patients with asthma and obesity
  • Discuss new developments in the management of obesity-related asthma and gaps in knowledge to be addressed by ongoing and future research
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit(s)
    The American Thoracic Society designates this for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.50 Participation
Publication Date: 
Credit Expires: 
Anne E. Dixon, MA, BM BCh, ATSFProfessor of MedicineUniversity of Vermont Larner College of MedicineChair; PresenterMitoQ: Research - investigator initiated
NIH: Advisory Committee - non-promotional
ABIM: Advisory Committee - non-promotional
Jun Ma, MD, PhDProfessor of MedicineUniversity of Illinois at Chicago, School of Public HealthPresenterNone
Erick Forno, MDAssociate Professor of PediatricsChildren's Hospital PittsburghChair; PresenterNone
Deepa Rastogi, MBBSAssociate Director of Clinical and Translational ScienceChildren's National Health SystemPresenterNone
Katherine Cahill, MDMedical Director of Clinical Asthma ResearchVanderbilt University Medical CenterPresenterNovartis: Advisory Committee for non-promotional
Third Harmonic: Consultant
Blueprint Medicines: Advisory Committee for non-promotional
GlaxoSmithKline: Advisory Committee for non-promotional
Sanofi: Advisory Committee for non-promotional
Sanofi Pasteur: Advisory Committee for non-promotional
Genentech: Advisory Committee for non-promotional
Ribon Therapeutics: Consultant
Verantos: Consultant
AstraZeneca: Advisory Committee for non-promotional
Novo Nordisk: Research - investigator initiated
Fernando Holguin, MDProfessor of Pulmonary MedicineUniversity of Colorado Health SystemsPresenterInsmed: Advisory Committee for non-promotional
FDA: Advisory Committee for non-promotional

Accreditation Statement

The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Disclosure Declaration

It is the policy of the ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. As an accredited CME provider, the ATS requires that its planners, reviewers and presenters comply with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. The ATS also requires specific disclosure of relationships with companies and organizations associated with tobacco or cannabis and prohibits or limits participation of faculty in official ATS activities, including CME, if any tobacco industry relationship or some types of cannabis industry relationships are present. To see the most recent policies regarding potential conflicts of interest as well as the mechanisms to resolve such conflicts, press the COI Policy link below.

This educational activity may include discussion of unapproved uses of a drug, product, or device. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions to Receive Credit

To earn credit for this course, follow these instructions:

  1. Launch and complete all modules by viewing every page in the module.
  2. After you complete the module(s), the post test will become available. You must pass the post these with a 70% score or better.
  3. Complete the Course Evaluation.
  4. Once you complete the modules, pass the post test and complete the evaluation, the system will grant you credit.
  5. To view your transcript and print your certificate, go to the My Account drop-down list. Then select Transcript.

Available Credit

  • 1.50 AMA PRA Category 1 Credit(s)
    The American Thoracic Society designates this for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.50 Participation
Please login or register to take this course.


To start this learning activity, press the Take Activity button. Then follow the on-screen instructions.

The system keeps track of your progress. If you close the activity and resume it later, it will re-start where you left off.